People genetically predisposed to schizophrenia are more vulnerable to psychotic experiences from cannabis
In 109,308 UK Biobank participants, cannabis use showed a strong dose-dependent association with psychotic experiences, and people with high schizophrenia polygenic risk were disproportionately affected.
Quick Facts
What This Study Found
Cannabis ever-use was associated with 67% greater adjusted odds of delusions of reference among individuals in the top fifth of schizophrenia polygenic risk, but only 7% greater adjusted odds among the bottom fifth. The cannabis-psychosis association was strongest for persecutory delusions and showed clear dose-dependence.
Key Numbers
Sample: 109,308 participants. Top PRS fifth: 67% increased odds of delusions of reference with cannabis use. Bottom PRS fifth: 7% increased odds. Strongest association: persecutory delusions. Cannabis users had earlier onset and more distressing psychotic experiences.
How They Did This
Cross-sectional study of 109,308 UK Biobank participants examining self-reported cannabis use against four types of psychotic experiences (auditory hallucinations, visual hallucinations, persecutory delusions, delusions of reference), stratified by schizophrenia polygenic risk scores.
Why This Research Matters
This is among the largest studies to show gene-environment interaction between schizophrenia genetic risk and cannabis use, supporting the hypothesis that genetically vulnerable individuals face greater psychosis risk from cannabis.
The Bigger Picture
These findings point toward a future where polygenic risk scores could inform personalized harm reduction, identifying individuals for whom cannabis use carries disproportionate psychosis risk.
What This Study Doesn't Tell Us
Cross-sectional design cannot establish temporal sequence. Self-reported cannabis use and psychotic experiences. UK Biobank participants may not be representative of the general population. Polygenic risk scores explain only a fraction of schizophrenia heritability.
Questions This Raises
- ?Could polygenic risk scores eventually be used clinically to counsel individuals about cannabis risk?
- ?Does the type of cannabis product (high-THC vs. balanced) modify this gene-environment interaction?
Trust & Context
- Key Stat:
- 67% increased odds of delusions in high genetic risk group vs. 7% in low risk
- Evidence Grade:
- Very large biobank sample with validated polygenic risk scores, though cross-sectional design limits causal inference.
- Study Age:
- Published in 2021.
- Original Title:
- Cannabis, schizophrenia genetic risk, and psychotic experiences: a cross-sectional study of 109,308 participants from the UK Biobank.
- Published In:
- Translational psychiatry, 11(1), 211 (2021)
- Authors:
- Wainberg, Michael, Jacobs, Grace R, di Forti, Marta(26), Tripathy, Shreejoy J
- Database ID:
- RTHC-03600
Evidence Hierarchy
A snapshot of a population at one point in time.
What do these levels mean? →Frequently Asked Questions
Does genetic risk change how cannabis affects psychosis risk?
Substantially. Cannabis ever-use was associated with 67% higher odds of delusions of reference in the top genetic risk group, compared to just 7% in the lowest risk group.
What type of psychotic experience was most strongly linked to cannabis?
Persecutory delusions (feeling targeted or followed) showed the strongest association with cannabis use across the full sample.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-03600APA
Wainberg, Michael; Jacobs, Grace R; di Forti, Marta; Tripathy, Shreejoy J. (2021). Cannabis, schizophrenia genetic risk, and psychotic experiences: a cross-sectional study of 109,308 participants from the UK Biobank.. Translational psychiatry, 11(1), 211. https://doi.org/10.1038/s41398-021-01330-w
MLA
Wainberg, Michael, et al. "Cannabis, schizophrenia genetic risk, and psychotic experiences: a cross-sectional study of 109,308 participants from the UK Biobank.." Translational psychiatry, 2021. https://doi.org/10.1038/s41398-021-01330-w
RethinkTHC
RethinkTHC Research Database. "Cannabis, schizophrenia genetic risk, and psychotic experien..." RTHC-03600. Retrieved from https://rethinkthc.com/research/wainberg-2021-cannabis-schizophrenia-genetic-risk
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.